Dajie Wang, MD
Pain Medicine · Philadelphia, PANPI 1285653048
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,021 of the $7,326 with a category attached, or 68.5%. Ironwood Pharmaceuticals, Inc accounts for 68.5% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $5,094 and has fallen 99.3% since, to $36 in 2025.
Across 20 payments — averaging $366.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ironwood Pharmaceuticals, Inc$5K
- Relievant Medsystems, Inc.$2K
- GRT US Holding, Inc.$158
- Abbott$124
- Curonix LLC$98
- Boston Scientific$26
- plus $60 from 3 others
Across 3 payments — averaging $623.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Siemens Medical Solutions USA, Inc.$2K
What the payments were for
- Consulting fees$5,02169%
- Travel & lodging$1,54921%
- Food & beverage$75610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ironwood Pharmaceuticals, Inc | 1 | $5,021 |
| Relievant Medsystems, Inc. | 9 | $1,840 |
| GRT US Holding, Inc. | 1 | $158 |
| Abbott | 3 | $124 |
| Curonix LLC | 1 | $98 |
| Boston Scientific | 2 | $26 |
| Globus Medical | 1 | $22 |
| Medtronic | 1 | $19 |
| Nevro Corp. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,326 in reported general payments places this provider in the 85th percentile of 294 pain medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 50 | $64,808 |
| Xtampza ErOxycodone Myristate | 30 | $41,470 |
| Oxycodone Hcl | 1,312 | $28,282 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 636 | $10,444 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 375 | $8,774 |
| Gabapentin | 582 | $8,547 |
| Fentanyl | 101 | $6,746 |
| Morphine Sulfate ErMorphine Sulfate | 139 | $3,413 |
| Diclofenac Sodium | 50 | $3,342 |
| Hydromorphone Hcl | 118 | $2,575 |
| EndocetOxycodone Hcl/Acetaminophen | 86 | $2,395 |
| Pregabalin | 161 | $2,297 |
| Methadone Hcl | 125 | $2,227 |
| Lidocaine | 53 | $1,947 |
| Naloxone Hcl | 26 | $1,809 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in Philadelphia
- Peter PryzbylkowskiPhiladelphia$506K
- Jonathan BeattyPhiladelphia$46K
- John FarrarPhiladelphia$37K
- Uplekh PurewalPhiladelphia$21K
- Megan LinehanPhiladelphia$12K
- Yeshvant NavalgundGreensburg$388K
- Jack SmithWilliamsport$324K
- Sanjay GuptaBala Cynwyd$241K
- Vwaire OrhurhuWilliamsport$191K
- Philip KimBryn Mawr$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.